GlassScriptPhysician profile
Natalia Abazeri
NPI 1174904106
$8,398.99
in general payments reported to CMS, 2019-2025
79 companies · $962 in 2025
The $962 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,232 · 2022: $2,129 · 2023: $1,974 · 2024: $1,102 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,492 · Education: $452 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $94.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.53 |
| Education | $451.99 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $94.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $743.96 | 2021-2024 | Qulipta, Botox, Ubrelvy |
| Daiichi Sankyo INC. | $335.04 | 2022-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $329.22 | 2022-2025 | Ninlaro |
| Janssen Biotech, INC. | $319.24 | 2022-2025 | Rybrevant, Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $297.44 | 2021-2025 | |
| Lilly USA, LLC | $276.54 | 2021-2025 | Mounjaro, Jaypirca, Verzenio |
| Gilead Sciences, INC. | $247.14 | 2023-2025 | Trodelvy, Biktarvy |
| Genentech USA, INC. | $232.91 | 2021-2025 | Phesgo, Polivy, Kadcyla |
| Seagen INC. | $230.84 | 2022-2024 | Padcev, Adcetris |
| Biohaven Pharmaceuticals, INC. | $215.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $196.88 | 2021-2024 | Lynparza, Enhertu |
| Incyte Corporation | $163.00 | 2022-2025 | Jakafi |
| Amgen INC. | $159.19 | 2021-2023 | Blincyto, Kyprolis |
| Emd Serono, INC. | $155.25 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $151.46 | 2021-2025 | Givlaari |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Abazeri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.